Abstract: Neovascular glaucoma (NVG) is regarded as refractory glaucoma secondary to retinal ischemia. Previous antiglaucoma drugs and surgeries present low therapeutic effect. Recently anti\|vascular endothelial growth factor (anti-VEGF) agent has been used as an adjunction for NVG comprehensive treatment, including trabeculectomy, drainage valve implantation, cyclophotocoagulation/cyclocryotherapy and vitrectomy etc. The antiangiogenic and antifibroblastic properties of anti-VEGF agents have shown great promise in reducing retinal ischemia, rapid regression of anterior segment neovascularization, preventing intra\| and post\|operative hyphema and improving the filtering bled, which effectively increase the operative successful rate, especially for NVG in the early stage. However, injection timing, safty and other aspects of anti-VEGF therapy in NVG treatment still need further study.  (Int Rev Ophthalmol, 2014, 38:   425-428)